ユニサイシブ・セラピューティクス
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.06 | $0 | -$8M |
| 2026 Q1 | -0.54 | $0 | -$6M |
| 2025 Q4 | -0.74 | $0 | -$8M |
| 2025 Q3 | -0.33 | $0 | -$6M |
| 2025 Q2 | -0.52 | $0 | -$8M |
| 2025 Q1 | -0.53 | $0 | -$9M |
| 2024 Q4 |
| -2.76 |
| $0 |
| -$7M |
| 2024 Q3 | -0.46 | $0 | -$9M |